Zhiyun Health (09955) reversed the market today, rising more than 16% in the intraday period. As of press release, it rose 9.09% to HK$3.48, with a turnover of HK$174 million.
The Zhitong Finance App learned that Zhiyun Health (09955) reversed the market today, rising more than 16% in the intraday period. As of press release, it rose 9.09% to HK$3.48, with a turnover of HK$174 million.
According to the news, Zhiyun Health announced in mid-April that the company launched the first digital employee, Yan Ruyu - Xiaoyu (as the name suggests, words must be done, action must be believed). By continuously exploring technological drivers in out-of-hospital solutions, digital employees optimize and upgrade the workflow and operation model of online to offline (O2O) operation services, freeing traditional personnel from complicated matters, and improving the overall efficiency of O2O operation services with technological efficiency combined with operational wisdom to better help pharmacies achieve the goals of increasing revenue, reducing costs, and improving efficiency.
It is worth noting that I learned from the company's official account that Hetang Jingdaglinet tablets under Zhiyun Health were approved on December 13, 2023, and officially launched nationwide on March 9, 2024. Up to now, commercialization with Tang Jing is progressing smoothly. The drug has covered 15 provinces (cities) including Shanghai, Shandong, Jiangsu, and Henan, and has cooperated with nearly 2,000 medical institutions.
CICC released a research report saying that in 2023, Zhiyun Health will explore the P2M (from patient to industry) development model, carry out strategic cooperation with pharmaceutical companies, and sell Zhiyun Health's own products with ownership, sales rights, or other exclusive rights, based on infrastructure layout within and outside the hospital. According to the research report, management publicly stated that the company's resource investment in 2023 will focus on the hospital sector, and it is expected that the P2M business will gradually expand into the pharmacy sector starting in 2024. The bank believes that with the expansion of the P2M business, the company's profit level is expected to improve further.